Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

February 28 -
March 1, 2014

Las Vegas, Nevada

Continuing Medical Education


Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum 14.5 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.


This program has been approved for 14.3 contact hours by the Oncology Nursing Society (ONS). The Continuing Education file number assigned to this offering is 0250.

This continuing nursing education activity was approved by the Oncology Nursing Society, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Physicians Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physicians assistants may receive a maximum of 14.5 hours of Category 1 credit for completing this program.

Who Should Attend

This educational activity is specifically designed for medical, surgical, and radiation oncologists, oncology nurses, nurse practitioners, pharmacists, and other healthcare professionals interested and/or involved in the care of patients with cancer.


After completing this activity, participants should be able to:

  • Apply advances in multidisciplinary care in diverse patient populations with solid tumors
  • Discuss how the latest clinical data in breast cancer management from the San Antonio Breast
  • Cancer Symposium has impacted routine clinical practice
  • Integrate appropriate therapeutic strategies in different disease settings for patients with gynecologic malignancies
  • Evaluate new directions in the treatment of gastrointestinal cancers, including colorectal cancer (CRC) and pancreatic adenocarcinoma
  • Describe recent advances in the treatment of patients with genitourinary malignancies, including renal cell carcinoma and prostate cancer
  • Identify the challenges and controversies in the optimal management of breast and prostate cancers
  • Treat patients with thyroid cancers effectively combining traditional and novel treatment modalities
  • Incorporate current evidence-based strategies into management approaches for patients with melanoma
  • Select the best therapeutic strategy for patients with NSCLC based on their molecular biomarker profile, tumor histology, co-morbidities, and emerging agents
  • Manage therapy-related adverse events, such as neurosensory toxicity, cardiotoxicity, and skeletal-related events, in patients with different malignancies
  • Employ mutation status and molecular biomarkers in guiding treatment decisions for different tumor types including CRC, non-small-cell lung cancer (NSCLC), and melanoma
  • Assess the benefits and risks of new and emerging therapies, including targeted agents and immunotherapeutic strategies, with potential to impact patient care in multiple tumor types
  • Formulate an optimal treatment plan for patients with diverse malignancies, including gastrointestinal, genitourinary, and thoracic malignancies, with considerations of current standards and emerging agents
  • Enroll patients in appropriate clinical trials based on patient and disease characteristics and potential benefits of the trial